Caveolin-1 expression in benign and malignant lesions of the breastReportar como inadecuado

Caveolin-1 expression in benign and malignant lesions of the breast - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

World Journal of Surgical Oncology

, 5:110

First Online: 03 October 2007Received: 23 April 2007Accepted: 03 October 2007


BackgroundCaveolin-1 is thought to have an important impact on both signal transduction and mediation of intracellular processes. Furthermore, it has been suggested that Caveolin-1 may contribute to certain steps of carcinogenesis in various types of cancer. We examined the potential clinical relevance of Caveolin-1 in normal, benign and malignant breast tissue specimens.

MethodsUsing tissue microarray TMA technology cases of invasive breast cancer, DCIS, benign breast disease i.e. fibroadenoma, sclerosing adenosis, ductal hyperplasia and radial scar and normal breast tissue were evaluated for Caveolin-1 expression. Immunohistochemical staining with an anti-Caveolin-1-antibody was performed. Staining intensity was quantified semiquantitatively. In invasive lesions staining results were correlated with clinical and pathological data.

ResultsNo Caveolin-1 expression was observed in epithelial cells of normal breast tissue n = 5, benign breast disease n = 295 and DCIS n = 108. However, Caveolin-1 expression was found in 32 of 109 cases of invasive breast carcinomas 29.4%. Caveolin-1 expression in invasive breast cancer could neither be correlated with survival parameters such as overall or disease-free survival nor with established clinical and pathological markers.

ConclusionIn this study we demonstrated expression of Caveolin-1 in one third of invasive breast cancers. A significant increase in Caveolin-1 expression was observed comparing invasive breast cancer to both benign breast tissue and non-invasive breast cancer. Since inhibitors of Caveolin-1 signalling are available, targeting Caveolin-1 in breast cancer may represent a potential option for future breast cancer treatment.

Electronic supplementary materialThe online version of this article doi:10.1186-1477-7819-5-110 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Cornelia Liedtke - Christian Kersting - Horst Bürger - Ludwig Kiesel - Pia Wülfing


Documentos relacionados